CivicaRx wants to change drug costs by working with pharma

Amy Baxter | | Health Exec | Policy & Regulations

CivicaRx, the not-for-profit entity created last year by a group of health systems and hospitals, is planning to achieve its goals of lowering drug prices and addressing shortages in hospitals by working directly with pharmaceutical companies and buying drugs, Bloomberg reported.

When the entity first came to fruition, its stated goal was to manufacture its own drugs after hospitals faced shortages for many common drugs. For now, it seems CivicaRx will serve as a marketplace entity, buying drugs from pharmaceutical companies and acting as a go-between for hospitals, according to Bloomberg.

“With that critical need, almost a national drug-shortage crisis, we had to discover what was the fastest way to get products into the market,” CivicaRx CEO Martin VanTrieste told Bloomberg.

See the full story below:

Nonprofit Trying to Upend Drug Costs Will Work With Pharma, Not Against It

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Mangione now faces federal charges, death penalty in murder of UHC CEO
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
DOJ sues CVS over unlawful opioid prescriptions and reimbursement
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders
Advancing AI for vascular surgery will require a commitment to data integrity

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.